Several teams have focused on RNA-based therapies, such as iGEM NJU-China (2016), who developed a small interfering RNA (siRNA) exosome specifically targeting integrin to modify mutated KRAS expression; KRAS being one of the most commonly mutated oncogenes in lung cancer and with integrin used as biomarker. The gene discussed is KRAS; the disease is lung carcinoma.